UC San Diego Health Sciences schools, institutes and centers are at the forefront of discovery and transformation.
UC San Diego researchers have launched a first-in-human Phase I clinical trial to assess the safety and efficacy of a gene therapy to deliver a key protein into the brains of persons with Alzheimer’s disease or Mild Cognitive Impairment, a condition that often precedes full-blown dementia.
Researchers at University of California San Diego School of Medicine identified new therapeutic targets for gastrointestinal stromal tumors (GISTs) that could lead to new treatment options for patients.
UC San Diego researchers report that individual immune response to SARS-CoV-2 may be limited by a set of variable genes that code for cell surface proteins essential for the adaptive immune system. The finding may help explain why COVID-19 immunity varies by individual.
The Psychedelics and Health Research Initiative at UC San Diego has received a $1.3 million grant from the Steven & Alexandra Cohen Foundation to fund a clinical trial investigating the therapeutic potential of psilocybin in treating phantom limb pain.
UC San Diego clinical trial suggests ivabradine may be effective in treating postural orthostatic tachycardia syndrome, a potential COVID-19 long-hauler symptom.
UC San Diego researchers discovered a single gene alteration that may help explain cognitive differences between modern humans and our predecessor, and used that information to develop Neanderthal-like brain organoids in the lab.
Forbes, May 29
San Diego Union Tribune, May 28
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
